DOI 10.1016/j.phymed.2026.158190
Momordin Ic targets SREBP1 to disrupt lipid homeostasis and trigger synergistic apoptosis-ferroptosis in triple-negative breast cancer.
Аннотация
BACKGROUND
Triple-negative breast cancer (TNBC) constitutes a clinically challenging disease subtype characterized by high metastatic potential and unsatisfactory treatment outcomes. Developing innovative pharmacological interventions is therefore critically important. The plant-derived compound Momordin Ic (MMD) has demonstrated preliminary anti-neoplastic activity; however, its therapeutic potential against TNBC and corresponding mechanisms require systematic investigation.
PURPOSE: This study aims to systematically investigate the therapeutic potential and underlying mechanisms of MMD against triple-negative breast cancer.
METHODS
MTT, EdU, colony formation, wound healing, transwell, flow cytometry, and xenograft mouse models. Mechanisms were explored using transcriptomic sequencing, molecular docking, cellular thermal shift assay (CETSA), and western blotting.
RESULTS
MMD substantially suppressed the growth, movement, and infiltration of TNBC cells, led to G2/M phase blockade and induced mitochondrial apoptosis together with ferroptosis. Mechanistically, MMD was found to directly bind to the transcription factor sterol regulatory element-binding protein 1 (SREBP1), suppressing its activity and downstream lipogenic genes (e.g. ACC1, SCD1). This led to disrupted lipid homeostasis, evidenced by reduced neutral lipid droplets and total cholesterol. Overexpression of SREBP1 partially reversed the anti-tumor effects of MMD. Furthermore, MMD robustly suppressed tumor growth in a xenograft model without observable toxicity.
CONCLUSIONS
Our findings indicate that MMD produces anti-TNBC responses through engagement of SREBP1 as a key functional mediator, causing metabolic disturbance and coordinated activation of apoptotic and ferroptotic pathways. These findings suggest that MMD could be further explored as a treatment candidate and highlight the SREBP1 pathway as a valuable target for TNBC treatment.
Предметные рубрики MeSH
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.